Thermo Fisher Scientific Inc. $TMO Shares Sold by Signature Estate & Investment Advisors LLC

Key Points

• Signature Estate & Investment Advisors LLC reduced its stake in Thermo Fisher Scientific by 23.0%, now holding 84,942 shares, making it 21st in their portfolio.
• Thermo Fisher Scientific has a market capitalization of $185.86 billion and reported $10.86 billion in revenue during the latest quarter, surpassing analyst estimates.
• The company announced a quarterly dividend of $0.43 per share, reflecting an annualized dividend yield of 0.3% and a payout ratio of 9.95%.

Signature Estate & Investment Advisors LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 84,942 shares of the medical research company's stock after selling 25,309 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.1% of Signature Estate & Investment Advisors LLC's holdings, making the stock its 21st largest holding. Signature Estate & Investment Advisors LLC's holdings in Thermo Fisher Scientific were worth $42,267,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Port Capital LLC lifted its position in Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after buying an additional 22 shares during the last quarter. Monograph Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after buying an additional 23 shares during the last quarter. Intergy Private Wealth LLC lifted its position in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after buying an additional 23 shares during the last quarter. Finally, Root Financial Partners LLC lifted its position in Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after buying an additional 24 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on TMO. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Barclays lifted their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Stock Down 1.1%

TMO traded down $5.38 on Wednesday, hitting $477.03. The company had a trading volume of 1,442,085 shares, compared to its average volume of 1,608,466. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The stock has a market capitalization of $180.13 billion, a price-to-earnings ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a fifty day moving average price of $464.58 and a 200-day moving average price of $452.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.